The 3C trial (CAMPATH, Calcineurin Inhibitor Reduction and Chronic Allograft Nephropathy)
This UK multi-centre prospective randomised trial in kidney transplantation is academically led and co-ordinated by Dr Richard Haynes at the Oxford Transplant Centre. This is currently recruiting in Royal Infirmary of Edinburgh and Principle Investigator is the transplant surgeon Mr Murat Akyol. This trial is comparing different anti-rejection medication regimes after transplant. Patients over 18 who are recipients of a kidney transplant from a living or deceased donor are eligible.
The following patients are ineligible; those who are receiving multiple organs, previous treatment with Campath-1H, patients with active infection or a history of cancer and patients who have lost a transplant within the previous 6 months not due to technical reasons. Trial participants will be followed-up for 5 years. On discharge from the Royal Infirmary in Edinburgh patients from the referring centres in the East of Scotland will be followed up in their local units with input from the research nurse in Edinburgh.
The induction therapy and early immunosuppression is determined by initial randomisation to be "Campath + Tacrolimus + Myfortic + NO STEROID" versus "Basiliximab + Tacro + MMMF/Myfortic + steroid". The trial involves a potential change of medication after 6 months due to the unique double randomisation design. The second randomisation at 6 months will assign participants to either "maintaining Tacrolimus" versus "switching to Sirolimus".
| Appendices << | (no next) |
